Individualization of leflunomide dosing in rheumatoid arthritis patients.

Hopkins, Ashley M; O'Doherty, Catherine E; Foster, David Jr; Upton, Richard N; Proudman, Susanna M; Wiese, Michael D

Hopkins, Ashley M; O'Doherty, Catherine E; Foster, David Jr; Upton, Richard N; Proudman, Susanna M; Wiese, Michael D.

Afiliação

Hopkins AM; University of South Australia, Sansom Institute for Health Research, School of Pharmacy & Medical Sciences, Frome Road, GPO Box 2471, Adelaide, South Australia, 5000, Australia.
O'Doherty CE; University of South Australia, Australian Centre for Pharmacometrics, School of Pharmacy & Medical Sciences, Frome Road, GPO Box 2471, Adelaide, South Australia, 5000, Australia.
Foster DJ; University of South Australia, Australian Centre for Pharmacometrics, School of Pharmacy & Medical Sciences, Frome Road, GPO Box 2471, Adelaide, South Australia, 5000, Australia.
Upton RN; University of South Australia, Australian Centre for Pharmacometrics, School of Pharmacy & Medical Sciences, Frome Road, GPO Box 2471, Adelaide, South Australia, 5000, Australia.
Proudman SM; University of South Australia, Australian Centre for Pharmacometrics, School of Pharmacy & Medical Sciences, Frome Road, GPO Box 2471, Adelaide, South Australia, 5000, Australia.
Wiese MD; Royal Adelaide Hospital, Department of Rheumatology, North Terrace, Adelaide, South Australia, 5000, Australia.

Per Med ; 11(4): 449-461, 2014 Jun.

Article em En | MEDLINE | ID: mdl-29783485

Palavras-chave

leflunomide; pharmacogenomics; rheumatoid arthritis; teriflunomide; therapeutic drug monitoring

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Per Med Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google